Literature DB >> 30940667

Comparing APLS and oranges: caution with the use of direct-acting oral anticoagulants (DOACs) instead of warfarin in the treatment of antiphospholipid syndrome (APLS).

Matthew Benger1, Jasper Vink1, Luke Blagdon Snell1, Karen Breen1.   

Abstract

A 63-year-old woman with known antiphospholipid syndrome (APLS) presented with catastrophic APLS and multiorgan dysfunction after a change in her anticoagulation from warfarin to rivaroxaban. Evidence suggests direct-acting oral anticoagulants (DOACs) like rivaroxaban may be less effective than warfarin in secondary prevention of thrombotic events in high-risk APLS patients. © BMJ Publishing Group Limited 2019. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  haematology (drugs and medicines); haematology (incl blood transfusion); systemic lupus erythematosus

Mesh：

Substances：

Year:  2019        PMID： 30940667      PMCID： PMC6453289          DOI： 10.1136/bcr-2018-227695

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN： 1757-790X


  11 in total

1.  Rivaroxaban versus warfarin in nonvalvular atrial fibrillation.

Authors:  Manesh R Patel; Kenneth W Mahaffey; Jyotsna Garg; Guohua Pan; Daniel E Singer; Werner Hacke; Günter Breithardt; Jonathan L Halperin; Graeme J Hankey; Jonathan P Piccini; Richard C Becker; Christopher C Nessel; John F Paolini; Scott D Berkowitz; Keith A A Fox; Robert M Califf
Journal:  N Engl J Med       Date:  2011-08-10       Impact factor: 91.245

2.  International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS).

Authors:  S Miyakis; M D Lockshin; T Atsumi; D W Branch; R L Brey; R Cervera; R H W M Derksen; P G DE Groot; T Koike; P L Meroni; G Reber; Y Shoenfeld; A Tincani; P G Vlachoyiannopoulos; S A Krilis
Journal:  J Thromb Haemost       Date:  2006-02       Impact factor: 5.824

3.  Antibody profiles for the diagnosis of antiphospholipid syndrome.

Authors:  Vittorio Pengo; Alessandra Biasiolo; Cinzia Pegoraro; Umberto Cucchini; Franco Noventa; Sabino Iliceto
Journal:  Thromb Haemost       Date:  2005-06       Impact factor: 5.249

4.  Evidence-based recommendations for the prevention and long-term management of thrombosis in antiphospholipid antibody-positive patients: report of a task force at the 13th International Congress on antiphospholipid antibodies.

Authors:  G Ruiz-Irastorza; M J Cuadrado; I Ruiz-Arruza; R Brey; M Crowther; R Derksen; D Erkan; S Krilis; S Machin; V Pengo; S Pierangeli; M Tektonidou; M Khamashta
Journal:  Lupus       Date:  2011-02       Impact factor: 2.911

5.  Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.

Authors:  Harry R Büller; Martin H Prins; Anthonie W A Lensin; Hervé Decousus; Barry F Jacobson; Erich Minar; Jaromir Chlumsky; Peter Verhamme; Phil Wells; Giancarlo Agnelli; Alexander Cohen; Scott D Berkowitz; Henri Bounameaux; Bruce L Davidson; Frank Misselwitz; Alex S Gallus; Gary E Raskob; Sebastian Schellong; Annelise Segers
Journal:  N Engl J Med       Date:  2012-03-26       Impact factor: 91.245

6.  Apixaban for the Secondary Prevention of Thrombosis Among Patients With Antiphospholipid Syndrome: Study Rationale and Design (ASTRO-APS).

Authors:  Scott C Woller; Scott M Stevens; David A Kaplan; D Ware Branch; Valerie T Aston; Emily L Wilson; Heather M Gallo; Eric G Johnson; Matthew T Rondina; James F Lloyd; R Scott Evans; C Gregory Elliott
Journal:  Clin Appl Thromb Hemost       Date:  2015-11-12       Impact factor: 2.389

7.  Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial.

Authors:  Alexander G G Turpie; Michael R Lassen; Bruce L Davidson; Kenneth A Bauer; Michael Gent; Louis M Kwong; Fred D Cushner; Paul A Lotke; Scott D Berkowitz; Tiemo J Bandel; Alice Benson; Frank Misselwitz; William D Fisher
Journal:  Lancet       Date:  2009-05-04       Impact factor: 79.321

Review 8.  Increased risk of thrombosis in antiphospholipid syndrome patients treated with direct oral anticoagulants. Results from an international patient-level data meta-analysis.

Authors:  Virginie Dufrost; Jessie Risse; Tatiana Reshetnyak; Maria Satybaldyeva; Yao Du; Xin-Xin Yan; Stella Salta; Grigorios Gerotziafas; Zhi-Cheng Jing; Ismaël Elalamy; Denis Wahl; Stéphane Zuily
Journal:  Autoimmun Rev       Date:  2018-08-11       Impact factor: 9.754

9.  Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome.

Authors:  Vittorio Pengo; Gentian Denas; Giacomo Zoppellaro; Seena Padayattil Jose; Ariela Hoxha; Amelia Ruffatti; Laura Andreoli; Angela Tincani; Caterina Cenci; Domenico Prisco; Tiziana Fierro; Paolo Gresele; Arturo Cafolla; Valeria De Micheli; Angelo Ghirarduzzi; Alberto Tosetto; Anna Falanga; Ida Martinelli; Sophie Testa; Doris Barcellona; Maria Gerosa; Alessandra Banzato
Journal:  Blood       Date:  2018-07-12       Impact factor: 22.113

10.  Rivaroxaban versus warfarin to treat patients with thrombotic antiphospholipid syndrome, with or without systemic lupus erythematosus (RAPS): a randomised, controlled, open-label, phase 2/3, non-inferiority trial.

Authors:  Hannah Cohen; Beverley J Hunt; Maria Efthymiou; Deepa R J Arachchillage; Ian J Mackie; Simon Clawson; Yvonne Sylvestre; Samuel J Machin; Maria L Bertolaccini; Maria Ruiz-Castellano; Nicola Muirhead; Caroline J Doré; Munther Khamashta; David A Isenberg
Journal:  Lancet Haematol       Date:  2016-09       Impact factor: 18.959
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.